Vaccines Manufacturing and Innovation Centre

G42 Healthcare and AstraZeneca Sign Agreement to Advance Life Sciences at BIO International Convention

Retrieved on: 
Tuesday, June 21, 2022
Solution, Oncology, Department of Health (Abu Dhabi), Department, AstraZeneca, Vaccines Manufacturing and Innovation Centre, Intelligence, United Arab Emirates, Health care, View, CEO, Research, Corporate Affairs, Letter, LOI, Doh, Emirate, Associate, Partnership, Patient, Cloud computing, Multimedia, Organization, Medical tourism, RWE, Pharmaceutical industry, G42

Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.

Key Points: 
  • Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.
  • G42 Healthcare and AstraZeneca initially signed a Declaration of Collaboration in December 2021.
  • Ashish Koshy, CEO of G42 Healthcare, said, "We value collaboration and believe the strategic partnership with AstraZeneca will yield incredible growth for the healthcare ecosystem.
  • Hicham Mirghani, Corporate Affairs Director GCC, AstraZeneca said, "We are excited about expanding our existing partnership with G42 Healthcare to further advance the healthcare sector in the country and region.

G42 Healthcare and AstraZeneca Sign Agreement to Advance Life Sciences at BIO International Convention

Retrieved on: 
Tuesday, June 21, 2022
Solution, Oncology, Department of Health (Abu Dhabi), Department, AstraZeneca, Vaccines Manufacturing and Innovation Centre, Intelligence, United Arab Emirates, Health care, CEO, Research, Corporate Affairs, Letter, LOI, Doh, Emirate, Associate, Partnership, Patient, Cloud computing, Organization, Medical tourism, RWE, Pharmaceutical industry, G42

Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.

Key Points: 
  • Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.
  • G42 Healthcare and AstraZeneca initially signed a Declaration of Collaboration in December 2021.
  • Ashish Koshy, CEO of G42 Healthcare, said, "We value collaboration and believe the strategic partnership with AstraZeneca will yield incredible growth for the healthcare ecosystem.
  • Hicham Mirghani, Corporate Affairs Director GCC, AstraZeneca said, "We are excited about expanding our existing partnership with G42 Healthcare to further advance the healthcare sector in the country and region.

G42 Healthcare and AstraZeneca Sign Agreement to Advance Life Sciences at BIO International Convention

Retrieved on: 
Tuesday, June 21, 2022
Solution, Oncology, Department of Health (Abu Dhabi), Department, AstraZeneca, Vaccines Manufacturing and Innovation Centre, Intelligence, United Arab Emirates, Health care, CEO, Research, Corporate Affairs, Letter, LOI, Doh, Emirate, Associate, Partnership, Patient, Cloud computing, Organization, Medical tourism, RWE, Pharmaceutical industry, G42

Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.

Key Points: 
  • Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.
  • G42 Healthcare and AstraZeneca initially signed a Declaration of Collaboration in December 2021.
  • Ashish Koshy, CEO of G42 Healthcare, said, "We value collaboration and believe the strategic partnership with AstraZeneca will yield incredible growth for the healthcare ecosystem.
  • Hicham Mirghani, Corporate Affairs Director GCC, AstraZeneca said, "We are excited about expanding our existing partnership with G42 Healthcare to further advance the healthcare sector in the country and region.

G42 Healthcare and AstraZeneca Sign Agreement to Advance Life Sciences at BIO International Convention

Retrieved on: 
Tuesday, June 21, 2022
Solution, Oncology, Department of Health (Abu Dhabi), Department, AstraZeneca, Vaccines Manufacturing and Innovation Centre, Intelligence, United Arab Emirates, Health care, CEO, Research, Corporate Affairs, Letter, LOI, Doh, Emirate, Associate, Partnership, Patient, Cloud computing, Organization, Medical tourism, RWE, Pharmaceutical industry, G42

Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.

Key Points: 
  • Witnessed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH, Hicham Mirghani, Corporate Affairs Director GCC at AstraZeneca and Dr. Fahed Al Marzooqi, Chief Operating Officer at G42 Healthcare, the agreement was signed by Ghaleb Al Ahdab Government Affairs, Associate Director Gulf at AstraZeneca, and Francesco Redivo Senior Director at G42 Healthcare during the BIO International Convention held in San Diego, California.
  • G42 Healthcare and AstraZeneca initially signed a Declaration of Collaboration in December 2021.
  • Ashish Koshy, CEO of G42 Healthcare, said, "We value collaboration and believe the strategic partnership with AstraZeneca will yield incredible growth for the healthcare ecosystem.
  • Hicham Mirghani, Corporate Affairs Director GCC, AstraZeneca said, "We are excited about expanding our existing partnership with G42 Healthcare to further advance the healthcare sector in the country and region.

Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in the UK and Across Europe

Retrieved on: 
Wednesday, April 6, 2022
United Kingdom, Harwell Science and Innovation Campus, Clinical trial, Board, Vaccines Manufacturing and Innovation Centre, Immunity, Vaccine, VMIC, Workforce, Industry, Technology, RNA transfection, Science, Solution, Imperial College London, Haverhill, Protein, Acquisition, Patient, Pharmaceutical industry, Fine chemical, Catalent

SOMERSET, N.J., April 6, 2022 /PRNewswire-PRWeb/ -- Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced the acquisition from Vaccine Manufacturing and Innovation Centre UK Limited (VMIC Ltd.) of a biologics development and manufacturing facility currently under construction near Oxford, U.K.

Key Points: 
  • It is expected that the new facility will employ more than 400 people and support public and private organizations seeking to develop and manufacture biotherapeutics.
  • "Our priority is to complete construction as soon as possible to be able to commence customer programs in 2022.
  • We will then integrate its capabilities within our existing network of biologics facilities across Europe to offer a flexible range of manufacturing, technology, and development solutions for the pipeline of thousands of development programs currently underway."
  • In Catalent, we've found a new owner who shares the vision for what we wanted to achieve and has safeguarded the interests of the workforce."

Winners Announced Of MCA Awards 2021 After A Record Year Of Entries

Retrieved on: 
Wednesday, November 10, 2021
Human resource policies, Industry, Private, Metropolitan, COVID-19, Public sector, Secretary of State for Business, Energy and Industrial Strategy, Innovation, IBM, Support, SME, VMIC, Ol-molog, Partner, Excellence, Leadership, Vaccine, Atos, Technology, Rising Star, International, Research, Courtauld Institute of Art, Strategy, MCA, FTSE, Tata Steel, Year, IBM Global Services, Business, Kimble, KPMG, EY, Ministry, Vaccines Manufacturing and Innovation Centre, Shell, BEIS, Simon-Kucher & Partners, PricewaterhouseCoopers, Social value, Consultant, Performance improvement, Human, Compliance, Public, Pharmaceutical industry, Audit

LONDON, Nov. 10, 2021 /PRNewswire/ -- The winners of the MCA Awards for 2021 have been announced at a face-to-face ceremony which took place recently with guests including clients, government officials, national media and leading executives across the private and public sector. Following a record year for the awards with an increase of 72% in entries, consultancy firms of all sizes and their clients were recognised for their award-winning projects and 7 individual winners were selected by the panel of 45 independent judges. The MCA Awards Ceremony, now in its 24th year, brought together the largest ever audience at the event in London, which was hosted by comedian and broadcaster, Sandi Toksvig OBE.

Key Points: 
  • Following a record year for the awards with an increase of 72% in entries, consultancy firms of all sizes and their clients were recognised for their award-winning projects and 7 individual winners were selected by the panel of 45 independent judges.
  • The MCA Awards Ceremony, now in its 24th year, brought together the largest ever audience at the event in London, which was hosted by comedian and broadcaster, Sandi Toksvig OBE.
  • Overall, there were 24 award categories with 14 project awards, 7 individual awards and 3 overall awards with 13 SMEs receiving awards as winners or highly commended across all categories.
  • Many of their achievements are recognised in the annual MCA Awards .